Epigral Reports Strong Q3 FY24-25 Growth Amidst Positive Financial Trends

Epigral, a midcap player in the chemicals industry, has recently undergone an evaluation adjustment reflecting its financial standing. The company has reported a notable performance in the third quarter of FY24-25, showcasing a robust annual growth rate in net sales of 23.14% and an operating profit growth of 19.71%. Over the past nine months, net sales reached Rs 1,922.50 crore, marking a significant increase of 36.88%.
The company has consistently delivered positive results for four consecutive quarters, with the highest quarterly PBDIT recorded at Rs 182.51 crore. Additionally, Epigral maintains a favorable debt-equity ratio of 0.64 times, indicating a solid financial structure.

In terms of market performance, Epigral has outperformed the broader market, generating a return of 85.28% over the last year, compared to the BSE 500's return of 8.66%. The company's return on capital employed (ROCE) stands at 22.1, reflecting its operational efficiency, although it is noted that the valuation appears expensive with an enterprise value to capital employed ratio of 4.

For more insights on Epigral's financial trends and performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.